The impact of illicit drug use and substance abuse treatment on adherence to HAART

AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

Volumn 19, Issue 9, 2007, Pages 1134-1140

  Hicks, P L ^a   Mulvey, K P ^b   Chander, G ^a   Fleishman, J A ^c   Josephs, J S ^a   Korthuis, P T ^d   Hellinger, J ^e   Gaist, P ^f   Gebo, K A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION   (United States)

^c AGENCY FOR HEALTHCARE RESEARCH AND QUALITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e Community Medical Alliance ^*  (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANALGESIC AGENT; ANTIRETROVIRUS AGENT; CANNABIS; COCAINE; DIAMORPHINE; PSYCHEDELIC AGENT; SEDATIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRINKING BEHAVIOR; ETHNICITY; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; RISK FACTOR; SEXUAL BEHAVIOR; SUBSTANCE ABUSE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG INTERACTIONS; ETHANOL; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PATIENT COMPLIANCE; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 36849077593     PISSN: 09540121     EISSN: 13600451     Source Type: Journal    
DOI: 10.1080/09540120701351888     Document Type: Article

References (23)

1. Arnsten, J.H., Demas, P.A., Grant, R.W., Gourevitch, M.N., Farzadegan, H., Howard, A. A., et al. (2002). Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. Journal of General Internal Medicine, 17, 377-381.
2. Bangsberg, D.R., Hecht, F.M., Charlebois, E.D., Zolopa, A.R., Holodniy, M., Sheiner, L., et al. (2000). Adherence to protease inhibitors, HIV-1 viral load and development of drug resistance in an indigent population. AIDS, 14, 357-366.
3. Chesney, M.A., Ickovics, J.R., Chambers, D.B., Gifford, A.L., Neidig, J., Zwickl, B., et al. (2000). Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG adherence instruments. Patient care committee & adherence working group of the outcomes committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12, 255-266.
4. Cook, R.L., Sereika, S.M., Hunt, S.C., Woodward, W.C., Erlen, J.A., & Conigliaro, J. (2001). Problem drinking and medication adherence among persons with HIV infection. Journal of General Internal Medicine, 16, 83-88.
5. Galvan, F.H., Bing, E.G., Fleishman, J.A., London, A.S., Caetano, R., Burnam, M.A., et al. (2002). The prevalence of alcohol consumption and heavy drinking among people with HIV in the US: Results from the HIV cost and services utilization study. Journal of Studies on Alcohol, 63, 179-186.
6. Gebo, K.A., Fleishman, J.A., Conviser, R., Reilly, E.D., Korthuis, P.T., Moore, R.D., et al. (2005a). Racial and gender disparities in receipt of highly active antiretroviral therapy persist in a multistate sample of HIV patients in 2001. Journal of Acquired Immune Deficiency Syndromes, 38, 96-103.
7. Gebo, K.A., Fleishman, J.A., Reilly, E.D., Moore, R.D., & HIV Research Network. (2005b). High rates of primary mycobacterium avium complex and pneumocystis jiroveci prophylaxis in the US. Medical Care, 43, 23-30.
8. Gifford, A.L., Bormann, J.E., Shively, M.J., Wright, B.C., Richman, D.D., & Bozzette, S.A. (2000). Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes, 23, 386-395.
9. Ickovics, J.R., Cameron, A., Zackin, R., Bassett, R., Chesney, M., Johnson, V.A., et al. (2002). Consequences and determinants of adherence to antiretroviral medication: Results from adult AIDS clinical trials group protocol 370. Antiviral Therapy, 7, 185-193.
10. Josephs, J.S., Fleishman, J.A., Gaist, P., & Gebo, K.A. (in press). Use of complementary and alternative medicines among a multistate, multisite cohort of people living with HIV/AIDS. HIV Medicine,
11. Lucas, G.M., Cheever, L.W., Chaisson, R.E., & Moore, R.D. (2001). Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. Journal of Acquired Immune Deficiency Syndromes, 27, 251-259.
12. Mannheimer, S., Friedland, G., Matts, J., Child, C., & Chesney, M. (2002). The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clinical Infectious Diseases, 34, 1115-1121.
13. Moatti, J.P., Carrieri, M.P., Spire, B., Gastaut, J.A., Cassuto, J.P., & Moreau, J. (2000). Adherence to HAART in French HIV-infected injecting drug users: The contribution of buprenorphine drug maintenance treatment. The MANIF 2000 study group. AIDS, 14, 151-155.
14. Moreno, A., Perez-Elias, M.J., Casado, J.L., Munoz, V., Antela, A., Dronda, F., et al. (2001). Long-term outcomes of protease inhibitor-based therapy in antiretroviral treatment-naive HIV-infected injection drug users on methadone maintenance programmes. AIDS, 15, 1068-1070.
15. NIAAA (1995). The physician's guide to helping patients with alcohol problems. Washington, DC: National Institutes of Health.
16. Palepu, A., Horton, N.J., Tibbetts, N., Meli, S., & Samet, J.H. (2004). Uptake and adherence to highly active antiretroviral therapy among HIV-infected people with alcohol and other substance use problems: The impact of substance abuse treatment. Addiction, 99, 361-368.
17. Palepu, A., Tyndall, M., Yip, B., O'Shaughnessy, M.V., Hogg, R.S., & Montaner, J.S. (2003). Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. Journal of Acquired Immune Deficiency Syndromes, 32, 522-526.
18. Paterson, D.L., Swindells, S., Mohr, J., Brester, M., Vergis, E.N., Squier, C., et al. (2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Annals of Internal Medicine, 133, 21-30.
19. Poundstone, K.E., Chaisson, R.E., & Moore, R.D. (2001). Differences in HIV disease progression by injection drug use and by sex in the era of highly active antiretroviral therapy. AIDS, 15, 1115-1123.
20. Sambamoorthi, U., Warner, L.A., Crystal, S., & Walkup, J. (2000). Drug abuse, methadone treatment and health services use among injection drug users with AIDS. Drug and Alcohol Dependence, 60, 77-89.
21. Tucker, J.S., Burnam, M.A., Sherbourne, C.D., Kung, F.Y., & Gifford, A.L. (2003). Substance use and mental health correlates of non-adherence to antiretroviral medications in a sample of patients with human immunodeficiency virus infection. American Journal of Medicine, 114, 573-580.
22. Turner, B.J., Laine, C., Cosler, L., & Hauck, W.W. (2003). Relationship of gender, depression and healthcare delivery with antiretroviral adherence in HIV-infected drug users. Journal of General Internal Medicine, 18, 248-257.
23. Warden, J., & Hunter, C. (2005). Buprenorphine and primary HIV care: Report of a forum for collaborative HIV research workshop. Washington, DC: George Washington University.